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SUMMARY. In March 2010, the Immunization Program of San Luis Province began a vaccination cam-
paign against influenza A H1N1 with monovalent and trivalent vaccines. Being this the first year that this
vaccine is used, and following the recommendations of WHO, we decided to develop pharmacovigilance
actions in order to assess its safety. Our objective was to identify, describe and analyze adverse reactions
associated with the vaccine against pandemic influenza occurring in health personnel of the Hospital San
Luis, through active monitoring of vaccinated employees. An epidemiological descriptive and transversal
study was carried out from March to June 2010. We found that 67 % (n = 809) reported adverse reactions
associated with the vaccine. Main adverse reactions reported included: pain at injection site (54 %), fa-
tigue, swelling and redness, malaise, headache and fever. The most frequent adverse reactions that have
been reported were non-serious and within expectations.
